At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 320 enrolled
Drug / intervention
Nivolumab +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 4 other interventions for Non-Hodgkin's Lymphoma and 2 related conditions. Completed, enrolled 320 participants across 43 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
CountriesBelgium, France, Greece, Italy, Poland, United States
CollaboratorsJanssen, LP
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartAug 2012
Primary CompletionSep 2020
Study CompletionJul 2024
TodayJul 2026
First PostedMay 7, 2012
Enrollment StartAug 2, 2012
Primary CompletionSep 25, 2020
Study CompletionJul 9, 2024
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 14.2 years ago
Interventions
Nivolumabbiological
Administered by intravenous (IV) infusion
Ipilimumabbiological
Administered by IV infusion
Lirilumabbiological
Administered by IV infusion
Daratumumabbiological
Administered by IV infusion
Pomalidomidedrug
Administered PO
Dexamethasonedrug
Administered PO and by IV infusion